Hayıroğlu Mert İlker, Çınar Tufan, Çinier Göksel, Yüksel Gizem, Pay Levent, Keskin Kıvanç, Coşkun Cahit, Ayan Gökçem, Çiçek Vedat, Tekkeşin Ahmet İlker
Department of Cardiology, Dr Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, Istanbul, 34668, Turkey.
Department of Cardiology, Haydarpasa Sultan II Abdulhamid Han Training and Research Hospital, Istanbul, 34668, Turkey.
Biomark Med. 2022 Apr;16(5):341-348. doi: 10.2217/bmm-2021-0991. Epub 2022 Mar 2.
This investigation aims to examine the prognostic utility of albumin concentrations for long-term all-cause mortality in patients undergoing permanent pacemaker implantation. A total of 1798 patients who received permanent pacemaker implantation were divided into quartiles according to serum albumin concentrations. The significance of albumin in predicting long-term mortality was compared in these quartiles. There was a higher rate of long-term mortality in the Q4 group compared with the Q1-3 groups (49.9 vs 15.8%). The risk of long-term mortality in the Q4 group was 3.6-times higher compared with the Q1-3 groups after adjustment for confounders. Serum albumin level at the time of device implantation has great value when assessing long-term mortality in patients with permanent pacemakers.
本研究旨在探讨白蛋白浓度对接受永久性起搏器植入患者长期全因死亡率的预后价值。共有1798例接受永久性起搏器植入的患者根据血清白蛋白浓度分为四分位数。在这些四分位数中比较白蛋白预测长期死亡率的显著性。与Q1-3组相比，Q4组的长期死亡率更高（49.9%对15.8%）。在调整混杂因素后，Q4组的长期死亡风险比Q1-3组高3.6倍。在评估永久性起搏器患者的长期死亡率时，装置植入时的血清白蛋白水平具有重要价值。
